28.04
-0.18(-0.64%)
Currency In USD
| Previous Close | 28.22 |
| Open | 28.14 |
| Day High | 28.69 |
| Day Low | 27.72 |
| 52-Week High | 62.58 |
| 52-Week Low | 23.42 |
| Volume | 528,229 |
| Average Volume | 682,763 |
| Market Cap | 1.62B |
| PE | 2.43 |
| EPS | 11.54 |
| Moving Average 50 Days | 29.97 |
| Moving Average 200 Days | 40.03 |
| Change | -0.18 |
If you invested $1000 in Agios Pharmaceuticals, Inc. (AGIO) 10 years ago, it would be worth $258.43 as of May 09, 2025 at a share price of $28.04. Whereas If you bought $1000 worth of Agios Pharmaceuticals, Inc. (AGIO) shares 5 years ago, it would be worth $635.4 as of May 09, 2025 at a share price of $28.04.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
GlobeNewswire Inc.
May 02, 2025 11:00 AM GMT
CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to presen
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
GlobeNewswire Inc.
Apr 17, 2025 11:00 AM GMT
CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a con
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
GlobeNewswire Inc.
Mar 05, 2025 10:52 PM GMT
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equ